- Home
- SNDX vs AIO Comparison
SNDX vs AIO Comparison
Compare SNDX & AIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNDX
- AIO
- Stock Information
- Founded
- SNDX 2005
- AIO 2019
- Country
- SNDX United States
- AIO United States
- Employees
- SNDX N/A
- AIO N/A
- Industry
- SNDX Biotechnology: Pharmaceutical Preparations
- AIO Finance/Investors Services
- Sector
- SNDX Health Care
- AIO Finance
- Exchange
- SNDX Nasdaq
- AIO Nasdaq
- Market Cap
- SNDX 974.9M
- AIO 826.9M
- IPO Year
- SNDX 2016
- AIO N/A
- Fundamental
- Price
- SNDX $11.54
- AIO $19.40
- Analyst Decision
- SNDX Strong Buy
- AIO
- Analyst Count
- SNDX 10
- AIO 0
- Target Price
- SNDX $36.20
- AIO N/A
- AVG Volume (30 Days)
- SNDX 1.9M
- AIO 141.5K
- Earning Date
- SNDX 05-07-2025
- AIO 01-01-0001
- Dividend Yield
- SNDX N/A
- AIO 9.05%
- EPS Growth
- SNDX N/A
- AIO N/A
- EPS
- SNDX N/A
- AIO N/A
- Revenue
- SNDX $23,680,000.00
- AIO N/A
- Revenue This Year
- SNDX $286.51
- AIO N/A
- Revenue Next Year
- SNDX $120.86
- AIO N/A
- P/E Ratio
- SNDX N/A
- AIO N/A
- Revenue Growth
- SNDX N/A
- AIO N/A
- 52 Week Low
- SNDX $9.66
- AIO $15.09
- 52 Week High
- SNDX $25.07
- AIO $20.25
- Technical
- Relative Strength Index (RSI)
- SNDX 44.37
- AIO 40.47
- Support Level
- SNDX $9.66
- AIO $19.10
- Resistance Level
- SNDX $11.61
- AIO $19.92
- Average True Range (ATR)
- SNDX 1.01
- AIO 0.89
- MACD
- SNDX 0.02
- AIO 0.10
- Stochastic Oscillator
- SNDX 56.12
- AIO 67.92
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.